Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer

Loft, M; Lok, SW; De Boer, R; Malik, L; Greenberg, S; Yeo, B; Anton, A; Nottage, M; Wong, V; Nott, L; Collins, IM; Torres, J; Barnett, F; Lombard, JM; Gibbs, P; Gately, L

Author(s): Loft, M; Lok, SW; De Boer, R; Malik, L; Greenberg, S; Yeo, B; Anton, A; Nottage, M; Wong, V; Nott, L; Collins, IM; Torres, J; Barnett, F; Lombard, JM; Gibbs, P; Gately, L;
Details: Publication Year 2023-02,Volume 198,Issue #1,Page 67-74
Journal Title: Breast Cancer Research and Treatment
Abstract: PURPOSE: Dual anti-HER2 targeted therapy and chemotherapy is the current first-line standard of care for HER2 + metastatic breast cancer (MBC), with endocrine therapy (ET) the backbone of treatment in hormone receptor positive (HR +) disease. The potential ET benefit in HER2 + /HR + patients is unknown as pivotal dual anti-HER2 clinical trials precluded ET use. METHODS: Real-world data from a multi-site registry of consecutive HER2 + MBC patients treated at clinician discretion were examined. Patients that were HR + (ER + and/or PR +) and had received first-line chemotherapy alongside trastuzumab and pertuzumab were explored. Of 362 patients in the registry, 215 were excluded due to being HR- (n = 210) or not receiving chemotherapy (n = 5). RESULTS: Of the 147 patients included, 91 (62%) received concurrent ET and 56 (38%) had not. Comparing the groups, there were no significant differences in age, performance status, metastatic sites, use of previous therapy and de novo metastatic disease. More patients with ER + PR + disease versus those with ER + PR- or ER-PR + received ET (73 vs 45%). The addition of ET was associated with significantly improved 5-year PFS (HR 0.58, CI 0.37-0.89, p = 0.014) and OS (HR 0.52, CI 0.31-0.90, p = 0.018), with no increase in adverse events noted. CONCLUSION: The addition of ET to first-line dual anti-HER2 therapy post chemotherapy in patients with HER2 + /HR + MBC was associated with major gains in PFS and OS with no safety concerns evident. Further studies of this combination are justified, along with studies of how best to integrate other agents that are active in this patient subset, including CDK4/6 inhibitors.
Publisher: Springer
Keywords: Humans; Female; *Breast Neoplasms/drug therapy/pathology; Receptor, ErbB-2; Trastuzumab; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Endocrine therapy; Her2; Hormone receptor-positive; Metastatic breast cancer
Research Division(s): Personalised Oncology
PubMed ID: 36624321
Publisher's Version: https://doi.org/10.1007/s10549-022-06856-1
Terms of Use/Rights Notice: Refer to copyright notice on published article.
Documents: s10549-022-06856-1.pdf - (0.65MB, application/pdf)

Creation Date: 2023-02-27 10:36:26

Last Modified: 2023-03-06 01:46:50